Private Equity
Strategies That Chinese Small and Medium-Sized Enterprises Use to Attract Venture Capital
Abstract Small and medium-sized enterprises (SMEs) contribute to China’s economic growth and help maintain social stability. However, SME business leaders have cited access to finance as an obstacle of SMEs’ survival and success. The purpose of this multiple case study was to identify main strategies SME entrepreneurs and business leaders used to attract venture capital […]
Venture Capital in Life Sciences (III): Monoclonal Antibodies in the Treatment of Ankylosing Spondylitis
The application of monoclonal antibody drugs is a relatively new innovation. Approximately 54% of monoclonal antibody drugs available are applied in various types of cancer, although clinical trials are also studying monoclonal drugs in autoimmune diseases, and sex organ transplants. When a monoclonal antibody attaches to a cancer cell, it can make the cancer cell […]
Venture Capital in Life Sciences (II): Pharmacogenomics and Personalized Medicine
Pharmacogenomics focuses on understanding the response rates and side effects of a treatment at the individual level. It analyzes the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with the efficacy or toxicity of a drug, hence improves clinical outcomes. The field of pharmacogenomics has applied in […]
Biomedicine: Healthcare Venture Capital’s Investment of 2014
As a venture capitalist, I believe the hottest investment of 2014 is in the healthcare sector. The beauty of healthcare investing lies in the fact that the demand for the sector is relatively inelastic; if a patient has a heart attack, or a new antitumor drug is discovered and developed, the demand will be completely […]
Private Equity Market Landscape – First Quarter 2014
The year of 2013 has been the most successful year for private equity firms since 2008, with 873 funds with an aggregate of $454 billion. In 2013, the private equity-backed buyout market was particularly strong; a total of 1,348 buyout exits were valued at $303 billion. Global merger and acquisition activity was dominated by a […]